NK - Nantkwest and ImmunityBio start dosing in global COVID-19 vaccine trials

NantKwest (NK) and privately-held ImmunityBio announce that the first cohorts of their South Africa and U.S. COVID-19 vaccine trials have received their initial doses of the T-cell-based COVID-19 vaccine candidate, hAd5.The trials aim to determine which route combination provides the strongest immune response and long-term immunity, as well as the vaccine candidate’s effectiveness against the growing number of mutated variants of the virus.In the three trials, the hAd5 vaccine candidate is being administered in a subcutaneous, oral, or sublingual formulation.  In total, 140 participants will be enrolled in the South African and U.S. trials.NantKwest entered into a reverse merger agreement with ImmunityBio to create an immunotherapy and cell therapy company focused on oncology and infectious disease, in December last year.

For further details see:

Nantkwest and ImmunityBio start dosing in global COVID-19 vaccine trials